张大伟 制图 ◎记者 何昕怡 受益于行业景气度日渐回暖、海外市场持续开拓、医药利好政策陆续落地，A股生物医药公司2025年在 韧性发展中不断交出创新的成绩单。 Wind数据显示，截至1月26日18时，已有超过90家A股生物医药公司发布2025年业绩预告，共有53家公 司预计实现盈利。从预告净利润增幅下限来看，有14家公司预计净利润倍增（剔除扭亏、减亏）。此 外，以岭药业、楚天科技等10家公司预计实现扭亏为盈，迪哲医药、盟科药业等14家公司同比实现减 亏。 其中，纳微科技核心业务中色谱填料和层析介质产品2025年销售收入预计实现约23%的增长，液相色谱 柱及样品前处理产品销售收入实现约32%的增长。公司持续加大国际市场拓展力度，预计实现国际业务 收入约8400万元，同比增长约79%。 国际化助力开拓增量市场 国际化业务是生物医药企业业绩增长的另一个助推器。 2025年初以来，受益于创新药行业发展、订单复苏明显，CXO公司表现强劲。作为CXO龙头，药明康 德预计：2025年实现营业收入454.56亿元，同比增长约15.84% ；实现归母净利润191.51亿元，同比增长 102.65%。 销售放量拉动业绩增长 在目 ...

Market Overview - The chemical pharmaceutical sector experienced a slight decline of 0.05% on January 21, with Sunflower leading the drop [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Performers - The following companies showed significant gains: - Aoheng Pharmaceutical (002437) closed at 3.51, up 10.03% with a trading volume of 1.9852 million shares and a transaction value of 693 million yuan [1] - Guobang Pharmaceutical (605507) closed at 26.96, up 6.81% with a trading volume of 132,600 shares and a transaction value of 357 million yuan [1] - Laimei Pharmaceutical (300006) closed at 5.24, up 6.50% with a trading volume of 670,800 shares and a transaction value of 345 million yuan [1] Underperformers - The following companies faced notable declines: - Sunflower (300111) closed at 4.64, down 6.07% with a trading volume of 1.514 million shares and a transaction value of 708 million yuan [2] - Hanshang Group (600774) closed at 10.94, down 6.01% with a trading volume of 436,600 shares and a transaction value of 470 million yuan [2] - Huabang Health (002004) closed at 5.40, down 4.42% with a trading volume of 1.1395 million shares and a transaction value of 618 million yuan [2] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 239 million yuan from institutional investors, while retail investors contributed a net inflow of 58.25 million yuan [2] - However, there was a net outflow of 297 million yuan from speculative funds [2] Individual Stock Capital Flow - Aoheng Pharmaceutical (002437) had a net inflow of 206 million yuan from institutional investors, accounting for 29.69% of its total trading [3] - Tonghua Golden Horse (000766) saw a net inflow of 74.79 million yuan from institutional investors, representing 14.69% [3] - Fuxing Pharmaceutical (600196) experienced a net inflow of 64.35 million yuan from institutional investors, making up 14.11% [3]

业绩增长的主要原因包括公司核心产品销量大幅增长，内部管理加强以及成本控制成效显著。此外，公 司在2025年12月收到出售广州誉衡生物科技有限公司股权的尾款及利息1.32亿元，这一款项计入投资收 益，属于非经常性损益。公司与会计师事务所就业绩预告相关财务数据进行了预沟通，双方不存在分 歧。 近日，誉衡药业发布公告称，预计公司2025年度业绩将显著增长，归母净利润预计为3.5亿元至4.2亿 元，比上年同期的2.33亿元增长50.37%至80.44%。 (编辑：杨燕 林辰)关键字： 医疗 （誉衡药业公告） ...

（文章来源：证券时报网） 资金面上看，誉衡药业近5日主力资金总体呈净流出状态，累计净流出3697.33万元，其中，上一交易日 主力资金全天净流出2380.00万元。 融资融券数据显示，该股最新（1月20日）两融余额3.16亿元，其中，融资余额为3.16亿元，近5日融资 余额合计减少1111.24万元，降幅为3.39%。（数据宝） 誉衡药业股价出现异动，截至今日9时31分，股价涨停，成交4836.66万股，成交金额1.66亿元，换手率 为2.30%，涨停板封单金额为7.93亿元，公司发布的最新业绩预告显示，预计2025年实现净利润3.50亿 元—4.20亿元，净利润同比增长50.37%—80.44%。 证券时报·数据宝统计显示，今日公布2025年业绩预告公司中，截至发稿股价较为强势的有中熔电气、 誉衡药业等，股价分别上涨19.27%、10.03%。 ...

（文章来源：证券时报网） 证券时报·数据宝统计显示，誉衡药业今日收于3.19元，下跌0.62%，日换手率为1.82%，成交额为1.22亿 元，近5日下跌1.54%。通过对2025年业绩预增50%以上的个股走势进行统计发现，预告发布后当日股价 上涨的占比67.06%，股价发布当日股价涨停的有3家。预告发布后5日股价上涨的占比75.29%。 资金面上，该股今日主力资金净流出2380.00万元，近5日资金净流出3697.33万元。最新（1月19日）两 融余额3.22亿元，其中，融资余额3.22亿元，环比前一交易日下降1.54%，近5日融资余额累计下降 1.06%。（数据宝） 誉衡药业（002437）1月20日发布2025年业绩预增公告，预计实现净利润为3.50亿元~4.20亿元，净利润 同比增长50.37%~80.44%。 ...

Group 1: New Stock Offerings - Medela's new stock offering has a subscription code of 920119, with an issue price of 41.88 yuan per share and a price-to-earnings ratio of 14.99 times, allowing a maximum subscription limit of 720,000 shares per account [2] Group 2: Fiscal Policy and Economic Measures - The Ministry of Finance will continue to implement a more proactive fiscal policy, aiming for increased total spending, improved structure, better efficiency, and stronger momentum, with necessary levels of fiscal deficit, total debt, and spending maintained through 2026 [3] - The Ministry of Finance has optimized the personal consumption loan interest subsidy policy, including credit card installment payments, removing restrictions on certain consumption areas, allowing all consumer loans to enjoy interest subsidies [3] - Starting April 1, 2026, export tax rebates for photovoltaic products will be canceled, and electronic product export tax rebates will be phased out over two years, promoting efficient resource use and guiding rational industrial structure adjustments [3] - Tax and fee preferential policies for community services such as elderly care, childcare, and housekeeping will continue, benefiting institutions providing these services [3] Group 3: Commodity Market Adjustments - The Shanghai Futures Exchange will adjust margin ratios and price fluctuation limits for futures contracts of copper, gold, and other commodities starting January 22, 2026 [4] - Domestic gasoline and diesel prices will increase by 85 yuan per ton due to rising international oil prices, marking the first price hike in 2026, with an average increase of 0.07 yuan per liter for 92 and 95 gasoline and 0 diesel [4] - Shanghai has released an action plan to enhance the linkage between spot and futures markets for non-ferrous metals, aiming to expand the international influence of "Shanghai prices" [4] Group 4: Company Earnings Forecasts - Huicheng Environmental Protection plans to increase its shareholding by 25 million to 50 million yuan [7] - JianTou Energy expects a net profit increase of approximately 253.38% year-on-year for 2025 [7] - Hikvision's performance report indicates a year-on-year growth of 18.46% in net profit attributable to shareholders for 2025 [7] - Longzi Co. anticipates a net profit increase of 245.25% to 302.8% year-on-year for 2025 [7] - Zhaoyan New Drug expects a net profit increase of 214% to 371% year-on-year for 2025 [8] - Huachen Equipment forecasts a net profit increase of 193.64% to 242.04% year-on-year for 2025 [8] - Qianyuan Power anticipates a net profit increase of 160% to 190% year-on-year for 2025 [8] - Jin Fang Energy expects a net profit increase of 123.97% to 193.7% year-on-year for 2025 [8] - Other companies such as Zhongfu Industrial, Batian Co., and Dongwei Technology also project significant year-on-year profit increases for 2025, ranging from 50% to over 300% [8][9]

证券日报网讯 1月20日，誉衡药业发布2025年度业绩预增公告称，公司预计2025年度归属于上市公司股 东的净利润为35，000.00万元至42，000.00万元，比上年同期增长50.37%至80.44%。 （文章来源：证券日报） ...

Core Viewpoint - Yuheng Pharmaceutical (002437) expects a significant increase in net profit for 2025, projecting a range of CNY 350 million to CNY 420 million, representing a year-on-year growth of 50.37% to 80.44% [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of CNY 350 million to CNY 420 million for 2025, compared to CNY 233 million in the previous year [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between CNY 185 million and CNY 220 million, reflecting a growth of 0.92% to 20.02% from CNY 183 million in the previous year [1] Group 2: Product Development and Market Position - Yuheng Pharmaceutical focuses on the research, production, and sales of pharmaceuticals, with a strong emphasis on high-barrier generic drugs, including pre-filled methotrexate injection [1] - The company has over 300 drug registration certificates, covering various therapeutic areas such as musculoskeletal, cardiovascular, vitamins and minerals, diabetes, analgesics, anti-infection, and anti-tumor [1] - Key products like multi-vitamin injections, potassium chloride sustained-release tablets, and others have maintained high market shares in their respective segments [2] Group 3: Sales and Marketing Strategy - The company primarily sells prescription drugs through hospitals, with some products available in retail pharmacies and e-commerce platforms [2] - Yuheng Pharmaceutical employs a refined招商 (investment promotion) and specialized academic promotion strategy for sales [2] - The company has a low export business proportion, currently limited to sodium phosphate injection to Uzbekistan, with future plans to expand exports in line with the Belt and Road Initiative [2] Group 4: Operational Efficiency - The company has achieved notable results in cost reduction and efficiency improvement, with decreases in both sales and management expenses compared to the same period in 2024 [3] - A non-recurring gain of CNY 132 million from the sale of equity in Guangzhou Yuheng Biotechnology Co., Ltd. is expected to be included in the 2025 investment income [3]

Core Viewpoint - The company expects a significant increase in net profit for 2025, projecting a range of 350 million to 420 million yuan, representing a year-on-year growth of 50.37% to 80.44% [1] Financial Performance - The basic earnings per share are estimated to be between 0.1597 yuan and 0.1917 yuan [1] - The increase in performance is attributed to strong sales growth of core products, including injectable multivitamins, potassium chloride sustained-release tablets, and other key medications [1] Cost Management - The company has improved internal management, leading to a noticeable reduction in sales and administrative expenses compared to the same period last year [1] Non-Recurring Income - In December 2025, the company received 132 million yuan from the sale of equity in Guangzhou Yuheng Biotechnology Co., Ltd., which will be included in the investment income for 2025 as a non-recurring gain [1]

Core Viewpoint - Yuheng Pharmaceutical (002437.SZ) expects a significant increase in net profit for the fiscal year 2025, projecting a range of CNY 350 million to CNY 420 million, representing a year-on-year growth of 50.37% to 80.44% [1] Financial Performance - The company anticipates a net profit attributable to shareholders of CNY 350 million to CNY 420 million, with a year-on-year increase of 50.37% to 80.44% [1] - The net profit after deducting non-recurring gains and losses is projected to be between CNY 185 million and CNY 220 million, reflecting a growth of 0.92% to 20.02% year-on-year [1] Product Performance - Key products such as injectable multivitamins, potassium chloride sustained-release tablets, and other medications have shown substantial and steady sales growth [1] - Additional products contributing to revenue growth include sitagliptin and metformin sustained-release tablets, flurbiprofen ester injection, and injectable papaverine hydrochloride [1]